- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Session 3: Discussant
Jan Berger, MD, MJ, The American Journal of Pharmacy Benefits editor-in-chief, follows Rebecca Killon's remarks with her own insight on the importance of diabetes medication adherence.
Jan Berger, MD, MJ, The American Journal of Pharmacy Benefits editor-in-chief, follows Rebecca Killon’s remarks with her own insight on the importance of diabetes medication adherence.
“I've waited 13 years for adherence to be an important issue. In 2003, when I first got somebody's attention, they looked at me like I was crazy,” said Dr Berger. “It was just a matter of [what] doctors would say to us when we would share with them that their patient was nonadherent. ‘It's not my problem,’ ‘ It's not my fault,’ ‘ It's the patient, we told them what to do.‘“
Dr Berger argues that the only way to truly have a breakthrough, is in the power of physician-patient relationships and alignment. Through better communication, continual learning, and realistic expectations, we can improve adherence rates.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs
September 20th 2024The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin costs for patients, prompting renewed calls for PBM reform.
Read More
Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes
September 5th 2024This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.
Read More
